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Sarcospan Regulates Cardiac Isoproterenol Response and Prevents
Duchenne Muscular Dystrophy–Associated Cardiomyopathy
Michelle S. Parvatiyar, PhD; Jamie L. Marshall, PhD; Reginald T. Nguyen, BS; Maria C. Jordan, MD; Vanitra A. Richardson, MS;
Kenneth P. Roos, PhD; Rachelle H. Crosbie-Watson, PhD
Background-—Duchenne muscular dystrophy is a fatal cardiac and skeletal muscle disease resulting from mutations in the
dystrophin gene. We have previously demonstrated that a dystrophin-associated protein, sarcospan (SSPN), ameliorated Duchenne
muscular dystrophy skeletal muscle degeneration by activating compensatory pathways that regulate muscle cell adhesion
(laminin-binding) to the extracellular matrix. Conversely, loss of SSPN destabilized skeletal muscle adhesion, hampered muscle
regeneration, and reduced force properties. Given the importance of SSPN to skeletal muscle, we investigated the consequences
of SSPN ablation in cardiac muscle and determined whether overexpression of SSPN into mdx mice ameliorates cardiac disease
symptoms associated with Duchenne muscular dystrophy cardiomyopathy.
Methods and Results-—SSPN-null mice exhibited cardiac enlargement, exacerbated cardiomyocyte hypertrophy, and increased
fibrosis in response to b-adrenergic challenge (isoproterenol; 0.8 mg/day per 2 weeks). Biochemical analysis of SSPN-null cardiac
muscle revealed reduced sarcolemma localization of many proteins with a known role in cardiomyopathy pathogenesis: dystrophin,
the sarcoglycans (a-, d-, and c-subunits), and b1D integrin. Transgenic overexpression of SSPN in Duchenne muscular dystrophy
mice (mdxTG) improved cardiomyofiber cell adhesion, sarcolemma integrity, cardiac functional parameters, as well as increased
expression of compensatory transmembrane proteins that mediate attachment to the extracellular matrix.
Conclusions-—SSPN regulates sarcolemmal expression of laminin-binding complexes that are critical to cardiac muscle function
and protects against transient and chronic injury, including inherited cardiomyopathy. ( J Am Heart Assoc. 2015;4:e002481 doi:
10.1161/JAHA.115.002481)
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D uchenne muscular dystrophy (DMD) is the most preva-lent, lethal genetic disorder of childhood and the most
common of the muscular dystrophies.1 Cardiomyopathy
develops by the 2nd and 3rd decade of life in over 90% of
cases. Genetic mutations in the dystrophin gene cause DMD,
resulting in loss of dystrophin protein and the entire
dystrophin-associated glycoprotein complex (DGC).1,2 The
dystrophin gene encodes a large protein (427 kDa) with
spectrin-like repeats that is localized to the sarcolemma of
skeletal and cardiac muscles.1,2 The DGC is a laminin-binding
adhesion complex that confers structural linkage between the
extracellular matrix and the intracellular actin cytoskeleton,
thereby providing protection to the sarcolemma from con-
traction-induced injury.2,3 Loss of the DGC reduces attach-
ment of the myofiber to its surrounding extracellular matrix
and renders the myofiber susceptible to contraction-induced
damage, eventually leading to muscle degeneration.3–6
The connection between cardiac disease and DMD has
been long recognized. Mutations linked to DMD are thought
to first exert their effects as skeletal muscle weakness with a
subsequent loss of ambulation, whereas cardiac decline
occurs in later decades of life. In contrast, X-linked cardiomy-
opathy, caused by mutations in the dystrophin gene, is a
distinct form of heart disease identified as a rapidly progres-
sive primary myocardial disorder that manifests in teenage
males as congestive heart failure. Female carriers (one copy
of the mutated dystrophin gene on the X chromosome) exhibit
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cardiac disease with later onset (fifth decade of life) and
typically slower progression.7 The mechanisms governing
differential expression of X-linked cardiomyopathy mutations
in the DMD gene remain unclear. Linkage analysis identified
genetic variants in the dystrophin gene (DMD), which
segregated with X-linked dilated cardiomyopathy without
identifiable skeletal muscle abnormalities in 2 separate
families.8,9 A characteristic of X-linked dilated cardiomyopa-
thy is that the mutated dystrophin transcript arises primarily
in cardiac tissue, with nearly normal to normal dystrophin
transcripts present in other tissue types. A search for distinct
regions of the dystrophin gene associated with primary
cardiac involvement revealed a number of mutations in the
extreme 50 end of the dystrophin gene that give rise to
X-linked dilated cardiomyopathy.9,10
Dystrophin is localized to the subsarcolemma, where it
associates with a transmembrane glycoprotein, b-dystrogly-
can (DG), which in turn associates with the extracellular
receptor for laminin, a-dystroglycan (DG).1,2 Dystrophin and
a/b-DG form a larger complex by interactions with 4 integral
membrane sarcoglycan subunits (a-, b-, d- and c-SGs).
Genetic mutations in the genes encoding a-, b-, d- and c-SG
cause autosomal recessive limb-girdle muscular dystrophy
(AR-LGMD) type 2D, 2E, 2C, and 2F, respectively.11–15 Severe
cardiac manifestations, including dilated cardiomyopathy, are
evident in cases of AR-LGMD-type 2E, 2C, and 2F, which are
caused by mutations in b- d-, and c-SG genes, respectively. In
sarcoglycanopathies, loss of one sarcoglycan leads to loss of
all 4 sarcoglycan components from the sarcolemma.16
Cardiomyopathy is rare in AR-LGMD type 2D, as loss of
a-SG is likely compensated by increased expression of
e-SG.17–19 Membrane instability is emerging as a critical
initiating event in DMD and sarcoglycan-deficient AR-LGMD;
therefore, mechanisms promoting restoration of cell surface–
extracellular matrix connections have great potential to
alleviate muscle damage and restore function. Sarcogly-
canopathies are additionally characterized by an infarct
pattern of fibrosis attributed to vasospasm.20–22
The abundance of the utrophin–glycoprotein complex
(UGC), a laminin-binding complex analogous to the DGC, is
increased in DMD muscle to partially compensate for the loss
of the DGC.23–28 Transgenic overexpression studies have
demonstrated that further increasing the levels of the UGC
can fully ameliorate DMD disease, and testing of compounds
that increase utrophin transcription activity is currently under
way.23 It is unknown whether increased abundance of
utrophin ameliorates skeletal and cardiac disease in sarco-
glycan-deficient AR-LGMD. Additionally, recent studies have
revealed that overexpression of a7b1 integrin ameliorates
DMD in relevant murine models by promoting muscle cell
adhesion in a manner similar to utrophin.29–31 Similarly,
integrin loss contributes to cell membrane instability and is
associated with increased fibrosis that compromises cardiac
muscle function and increases susceptibility to arrhyth-
mias.32,33 Under pathological conditions, integrins colocalize
to the borders of cardiac fibrosis.34,35
Sarcospan (SSPN) is a tetraspanin-like protein that facil-
itates protein interactions between transmembrane proteins,
and associates with the 3 major adhesion complexes in
skeletal muscle including the DGC, UGC, and a7b1 inte-
grin.36–38 This unique biochemical property of SSPN makes it
an attractive therapeutic target for the muscular dystrophies.
Transgenic overexpression of SSPN increased the levels of
dystrophin at the sarcolemma in wild-type skeletal muscle. In
dystrophin-deficient murine models of DMD (mdx mice), SSPN
increased expression of the UGC and a7b1D integrin at the
mdx sarcolemma, leading to restoration of laminin-binding
and amelioration of skeletal muscle disease.39,40 Recent
studies have revealed that SSPN also mediates efficient
skeletal muscle regeneration after transient injury by regulat-
ing intracellular Akt signaling pathways that control these
processes.39,40 Lebakken and colleagues initially reported
that SSPN ablation did not alter DGC protein abundance or
skeletal muscle function in young mice.41 However, investi-
gation of older SSPN-null mice revealed an increased
susceptibility to eccentric contraction-induced damage due
to reduction of DGC and UGC at the sarcolemma.42 Since
SSPN is fundamental to maintenance of cellular integrity of
skeletal muscle, we investigated its role in SSPN-deficient
cardiac muscle in the current study and tested the ability of
SSPN to prevent DMD-associated cardiomyopathy.
Methods
Animal Models
All mice used in this study were males and different ages are
listed in the figure legends. The SSPN-deficientmice used in this
study were a generous gift from Dr Kevin P. Campbell
(University of Iowa Medical School, Iowa City, IA). SSPN-null
mice were maintained using a SSPN-null9SSPN-null breeding
strategy. Male WT C57BL/6J mice were maintained and age
matched with SSPN-null progeny to generate age-matched
controls. Mice were genotyped at various time points to ensure
correct genetics. Generation and characterization of human
SSPN-transgenic mdxTG mice have been described previously
by our group. The breeding strategy employed wasmdx:human
SSPN (Line 3) TG male9mdx female crossings. Age-matched
mdx mice that resulted from this cross were used as controls.
Mice were maintained in the Terasaki Life Sciences Vivarium,
and all procedures followed guidelines established by the
Institutional Animal Care and Use Committee at the University
of California, Los Angeles; approval for these studies was
granted by the UCLA Animal Welfare Assurance.
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Histochemical and Immunofluorescence Assays
H&E staining was used to visualize changes in tissue
architecture including myocyte disarray, hypertrophy, and
fibrosis. Longitudinal sections of fresh frozen cardiac tissue
(7 lm) were acclimated to room temperature for 15 minutes
before staining and stained with H&E obtained from Thermo
Fisher Scientific and according to previously published
methods.43 Masson’s Trichrome staining was utilized for
collagen detection in cardiac tissue according to described
methods.44 Cardiac section images were captured under
identical conditions using an Axioplan 2 fluorescent micro-
scope equipped with a Plan Neofluar 409 NI 1.3 oil
differential interference contrast objective and the Axiovision
Rel 4.5 software (Carl Zeiss, Inc). Average fiber area
measurements were performed by manually measuring the
area of fiber bundles in transversely cut cardiac sections using
Thermo Scientific myImage Analysis v1.1 software. A similar
procedure was used to measure fibrotic areas compared
relative to total area (%). Immunofluorescence assays were
performed and visualized as described.39
Protein Preparations and Immunoblot Analysis
Cardiac muscle was snap-frozen in liquid nitrogen and stored
immediately at 80°C, and tissue samples were prepared as
described for immunoblot analysis. Prior to tissue collection,
mice were euthanized using isoflurane administered using a
nose cone. For the DG pulldown assays, cardiac muscle was
extracted in 0.1% digitonin and adhesion complexes were
enriched by wheat germ agglutinin (sWGA) and eluted with
0.3 mol/L N-acetylglucosamine (Sigma-Aldrich).42 Total pro-
tein samples were prepared in ice-cold radioimmunoprecipi-
tation assay buffer; 89901 (Thermo Scientific) along with
phosphatase inibitors. Equal concentrations of samples were
resolved by SDS-PAGE (4–20% PreciseTM Protein Gels) and
transferred to nitrocellulose membranes. Immunoblots were
performed using 30 lg of sWGA eluates or 60 lg of
radioimmunoprecipitation assay lysate. The following primary
antibodies were used: dystrophin (MANDYS1, 1:200; Devel-
opment Studies Hybridoma Bank), Utr (MANCHO3, 1:50;
Development Studies Hybridoma Bank), a-DG IIH6 (sc-53987,
1:500; Santa Cruz Biotechnology, Inc), b-DG (MANDAG2,
1:250; Development Studies Hybridoma Bank), a-SG (VP-
A105, 1:100; Vector Labs), b-SG (VP-B206, 1:100; Vector
Labs), d-SG (VP-D501, 1:50; Vector Labs), c-SG (VP-G803,
1:100; Vector Labs), b1D integrin (MAB1900, 1:200; Chemi-
con), mouse SSPN (R18, 1:100; in house), human SSPN (R15;
in house), and GAPDH (MAB374, 1:50 000; Chemicon).
Coomassie blue staining was used as an additional loading
control. Horseradish peroxidase–conjugated anti-rabbit IgG
(GE Healthcare), anti-mouse IgG (GE Healthcare) were used at
1:2000 dilutions in 5% BLOTTO and incubated at room
temperature for 3 hours. Blots were developed using
enhanced chemiluminescence (SuperSignal West Pico Chemi-
luminescent Substrate; Thermo Scientific). Densitometry was
performed using Thermo Scientific myImage analysis, and the
average integrated density values of the protein of interest
were determined and normalized to controls.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Total RNA was extracted from hearts of 12-month-old mice
using TRIzol Reagent (Ambion) according to manufacturer’s
instructions, RNA concentrations were determined using the
NanoDrop 1000 (Thermo Scientific), and reverse transcription
was performed with 0.5 lg RNA using the iScript cDNA
Synthesis kit (Bio-Rad Laboratories, Inc). Changes in relative
gene expression were quantified using the 2ΔΔ CT method and
normalized to an internal control mL32 (a ribosomal protein
that does not vary in conditions tested here). Quantitative
reverse transcription-–polymerase chain reaction was per-
formed in duplicate per sample using the TaqMan ABI PRISM
7900 (Applied Biosystems) according to the instructions
provided by in the SsoFastTM EvaGreen Kit (Bio-Rad Labo-
ratories, Inc).
Evans Blue Dye Uptake
Sarcolemmal membrane damage was assessed using an
Evans blue dye (EBD) tracer analysis. Mice were injected
peritoneally with EBD and maintained for 12 hours prior to
euthanasia by isoflurane administration. The percentage of
EBD-positive fibers (fluoresce red) against laminin counter-
stain (green) was obtained by quantitating the number of EBD-
positive myofibers/total number of myofibers. Sarcolemmal
membrane damage was assessed using an EBD tracer
analysis that was performed by intraperitoneal injection of
1 g EBD/10 g body weight in 12- to 14-month-old mice,
8 hours prior to dissection.
Laminin Overlay
A nitrocellulose membrane was prepared as described in the
immunoblot analysis methods and sWGA enriched eluates
were blocked with 5% bovine serum albumin (BSA) in laminin
binding buffer (LBB; 10 mmol/L triethanolamine, 140 mmol/
L NaCl, 1 mmol/L MgCl2, 1 mmol/L CaCl2, pH 7.6) then
incubated with 20 nmol/L mouse ultrapure Engelbreth–
Holm–Swarm laminin (354239, BD Biosciences) in laminin
binding buffer for 6 hours at 4°C. Subsequently, the
membranes were washed in laminin binding buffer-tween
(LBBT) and incubated with primary rabbit anti-laminin
DOI: 10.1161/JAHA.115.002481 Journal of the American Heart Association 3
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(L9393, 1:5000; Sigma) secondary horseradish peroxidase–
conjugated anti-rabbit IgG (GE Healthcare) and blots were
developed using standard techniques.
Creatine Kinase Measurements
The Stanbio CK-MB Liqui-UV kit was used to quantitatively
determine levels of CK-MB (cardiac iso-enzyme) in the blood
serum of wild-type, mdx and mdxTG mice following procedures
outlined by the manufacturer. Blood was collected from mice
retroorbitally in red-cap blood collection tubes (no anticoag-
ulant) and was allowed to clot at room temperature for
30 minutes and spun for 10 minutes at 2000g in a refriger-
ated centrifuge. The sera were collected and immediately
stored at 80°C. A Molecular Devices Spectra Max (ML) plate
reader was used and absorbance readings were taken at
340 nm and 1-cm light path. The following equation was used
to determine % CK-MB Activity=CK-MB Activity (U/L)9100/
Total CK activity (U/L).
Echocardiography
Left ventricular (LV) size, mass, wall thickness, ventricular and
valve function, and Doppler blood flows were obtained using
methods previously described and animals were anesthesized
using inhaled isoflurane.45,46 Mice were lightly sedated with
isoflurane vaporized in oxygen (2.5% induction, 1.0% mainte-
nance), weighed, and their chests were shaved. The mice
were positioned in the left lateral decubitus position for
ultrasonic imaging with an Acuson Sequoia C256 equipped
with a 15L8 15 MHz probe (Siemens Medical Solutions,
Malvern, PA). Needle electrodes attached to the extremities
allowed simultaneous recording of the ECG to determine
timing and heart rates. Also, the long-axis, short-axis, and
apical views were used to obtain 2-dimensional, M-mode, and
spectral Doppler images at physiological heart rates (500–
600 bpm). Measurements were made using the Acuson
and AccessPoint software (Freeland Systems, LLC, Santa Fe,
NM).
Chronic b-Adrenergic Stimulation
Mice were anesthetized with isoflurane and miniosmotic
pumps (Alzet, Durect Corp, Cupertino, CA), filled with sterile
saline (sham) or isoproterenol, were implanted subcuta-
neously to challenge the myocardium with isoproterenol
(0.8 mg/day) (dosage determined empirically) for 14 days,
and mice were monitored by echocardiography.47 The dose
and length of experiment were chosen that allowed changes
in cardiac function but not high enough to cause lethality or b-
receptor desensensitization. The sham- and isoproterenol-
treated mice were echoed prior to pump implantation and at
the end of the study to identify any ventricular remodeling and
functional changes from baseline.
Statistics
All values in the text and figures are presented as meanSEM.
The statistical significance of the differences between means
was assessed using Sigma Plot 13.0 software. One-way ANOVA
with Bonferroni post hoc test was used to determine signi-
ficance among different treatment groups. Data that failed the
assumptions of normality were analyzed using the nonpara-
metric Kruskal–Wallis test. The statistical test utilized for each
set of data is indicated in the figure legends. P values of <0.05
were considered significant, and significant and near-significant
P values are reported in the figure legends.
Results
In skeletal muscle, ablation of SSPN significantly reduces
skeletal muscle function as determined by lowered specific
diaphragmatic force production in SSPN-null mice. The
decreased force between the first and the fifth eccentric
contraction observed in SSPN-null diaphragms was evidence
that loss of SSPN weakens the sarcolemma.42 Mechanistic
studies revealed that SSPN-deficiency reduced abundance of
laminin-binding adhesion complexes at the sarcolemma, ren-
dering the myofiber susceptible to contraction-induced
injury.42 Based on these findings, we tested the hypothesis
that SSPN deficiency would negatively impact cardiac function.
Cardiac Morphology in Isoproterenol-Treated
SSPN-Null Mice
Tetraspanin-like proteins, such as SSPN, often reveal their
dysfunction when subjected to conditions of chronic stress.48
This study was founded upon an initial observation that 12-
month-old SSPN-null mice exhibited cardiac enlargement
compared to wild-type mice. To further investigate the effects
of SSPN deficiency on cardiac morphology, we exposed 12-
month-old SSPN-null mice to a 2-week b-adrenergic challenge
using continual administration of isoproterenol (0.8 mg/day)
via osmotic pump. Comparison of body weights revealed that
SSPN-null mice were heavier after isoproterenol-treatment
compared to wild-type mice (Figure 1A, left panel). Both
isoproterenol and saline-treated SSPN-null mice exhibited
significantly greater heart weight/body weight ratios (HWt/
BWt; mg/g) compared to the relevant wild-type controls
(Figure 1A, right panel). After saline administration, HWt/BWt
ratios for wild-type and SSPN-null mice were 5.320.67 and
6.580.27 mg/g, respectively, whereas after isoproterenol
treatment, they increased to 6.630.58 and 7.410.64 mg/
DOI: 10.1161/JAHA.115.002481 Journal of the American Heart Association 4
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g for wild-type and SSPN-null mice, respectively. We observed
that SSPN-null hearts were larger than wild-type hearts after
isoproterenol treatment, as visualized in wet-mount samples
(Figure 1B).
Cardiac Dysfunction in SSPN-Null Hearts
Echocardiography was used to evaluate cardiac function of
SSPN-null mice relative to controls. All parameters at baseline
and after treatment are summarized in Table 1. Increasing
age further exacerbated hypertrophy in SSPN-null hearts; at
18 months, SSPN-null hearts (95.896.71 mg) exhibited
greater left ventricular mass (LV mass) relative to age-
matched wild-type controls (67.182.89 mg) (Figure 2A).
The LV mass of wild-type mice remained unchanged between
12 and 18 months of age (12 months, 67.543.76 mg;
18 months, 67.182.89 mg). LV mass was significantly
increased in 12-month-old SSPN-null mice after isoproterenol
treatment (116.112.7 mg) compared with saline-adminis-
tered controls (82.618 mg) as depicted in Figure 2B.
However, saline-administered SSPN-null and wild-type mice
had similar LV masses at 12 months of age.
Echocardiography revealed additional parameters that
were negatively impacted in SSPN-null mice after isopro-
terenol treatment. Posterior wall thickness and interventric-
ular septum thickness were elevated in treated SSPN-nulls
relative to treated wild-type controls (Table 1). Additionally,
the left ventricular end diastolic dimension of isoproterenol-
treated SSPN-null hearts was statistically increased relative to
saline-treated SSPN-nulls, while isoproterenol did not affect
left ventricular end diastolic dimension (LVEDD) from wild-
type mice (Figure 2C). Upon isoproterenol treatment, SSPN-
null hearts exhibited greater left ventricular end systolic
dimension (LVESD) compared with wild-type hearts, which
responded to isoproterenol treatment in a predictable manner
with a decrease in LVESD (Figure 2D). Specifically, treated
SSPN-null hearts displayed left ventricular end systolic
dimension values of 3.30.2 mm compared with isopro-
A
B
Figure 1. Cardiac morphology is altered in isoproterenol-treated SSPN-null mice. Mice in this study were
designated as saline-treated (Sal) or isoproterenol-treated (Iso) for both SSPN-null (SSPN/) and WT mice.
All mice were 12 months of age. A, BWts of WT and SSPN/ mice after saline- or isoproterenol-treatment
and the HWt/BWt ratio (mg/g) were compared for saline- and isoproterenol-treated mice. Data are shown
as mean and error expressed as SEM. B, Representative wet mount images of hearts from treated and
untreated WT and SSPN/ mice used in this study. In (A) BWt (g) (left panel) and HWt/BWt (right panel)
measurements were plotted for saline (Sal, WT, n=4 and SSPN/ mice, n=3) and isoproterenol (Iso, both
WT and SSPN/ mice, n=7) treatment for each genotype after completion of the 2-week study. P-values
<0.05 were considered significant and statistics were calculated using 1-way ANOVA with Bonferroni post
hoc test. For BWt (g) left panel, *P=0.022 SSPN/ (Sal) vs SSPN/ (Iso), P=0.115 SSPN/ (Iso) vs WT
(Iso), P=0.408 SSPN/ (Iso) vs WT (Sal). For HWt/BWt (mg/g) right panel, *P<0.001 SSPN/ (Iso) vs WT
(Sal), **P=0.016 WT (Iso) vs WT (Sal), P=0.363 SSPN/ (Iso) vs SSPN/ (Sal), P=0.149 SSPN/ (Iso) vs
WT (Iso). HWt/BWt indicates heart weight/body weight; SSPN, sarcospan; WT, wild-type.
DOI: 10.1161/JAHA.115.002481 Journal of the American Heart Association 5
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terenol treated wild-type control values of 2.370.6 mm
(Table 1). Representative M-mode images (Figure S1) showed
enlargement of the left cardiac chamber in SSPN-nulls after
isoproterenol stimulation. Overall, cardiac function in SSPN-
null mice was significantly altered after isoproterenol treat-
ment, evident as LV hypertrophy and dilatation.
LV function following b-adrenergic stimulation was
assessed in 12-month-old SSPN-null and wild-type mice using
echocardiography. As expected, isoproterenol increased LV
contractility, as revealed by ejection fraction values (LVEF) in
hearts of wild-type mice. Specifically, LVEF values for isopro-
terenol-treated wild-type mice was 80.66.9% compared with
saline-administered wild-type controls (64.59.6%). Baseline
LVEF values were similar for wild-type and SSPN-nulls
(Table 1). In obvious contrast to the wild-type response to
isoproterenol, SSPN-null hearts exhibit an attenuated contrac-
tile response to isoproterenol, as revealed by LVEF (%) values
of 64.53.8% (Figure 2E). Echocardiographic analysis also
revealed large differences in LV fractional shortening (LVFS) in
SSPN-nulls upon isoproterenol challenge. In response to b-
receptor agonists, wild-type hearts responded with increased
LVFS as evidenced by values after saline treatment
(30.97.4%) and isoproterenol treatment (44.47.2%) (Fig-
ure 2F). However, we observed that SSPN-null mice responded
aberrantly to isoproterenol administration, evident by the
depressed (LVFS) (Sal, 34.035.0%; Iso, 30.02.4%). Despite
these changes, SSPN-nulls maintain cardiac function as shown
by the preserved ejection fraction and modest decreases in
fractional shortening (Figure 2E and 2F). Furthermore, isopro-
terenol treatment affected diastolic dysfunction, as revealed
by E/A ratios (early peak/atrial peak flow velocities) that were
significantly increased after isoproterenol stimulation in SSPN-
null hearts compared with wild-type (Table 1).
Isoproterenol Treatment Accelerates Cardiac
Pathology in SSPN-Null Mice
Analysis of cardiac muscle cryosections from 12-month-old
SSPN-null mice revealed significant interstitial and extensive
replacement fibrosis after isoproterenol administration (Fig-
ure 3A). Fibrosis in isoproterenol-treated wild-type hearts was
not as extensive (Figure 3A). Masson’s trichrome staining
further supported widespread collagen deposition in SSPN-
null hearts (Figure 3B). Quantification of fibrosis in cross-
sections from isoproterenol-treated SSPN-null hearts demon-
strated that 12% of the total area was fibrotic, whereas wild-
type hearts exhibited 4.6% fibrosis (Figure 3C). In saline-
treated SSPN-nulls, 2% of the total area was fibrotic
compared to 0.5% total area for wild-type (Figure 3C).
Additionally, we found that the cross-sectional areas of fibers
were differentially affected by isoproterenol treatment in
SSPN-nulls (Figure 3D and 3E).
Table 1. Summary of Echocardiographic Data Obtained From b-Adrenergic Stimulation of WT and SSPN-null Mice
Baseline Saline Isoproterenol
WT (n=7)
SSPN/
(n=7) WT (n=4)
SSPN/
(n=4) WT (n=7) SSPN/ (n=7)
ECHO parameter
HR, bpm 508.624.6 526.315.6 517.6421.1 535.1930.8 626.9812.7§ 598.121.7
LVEDD, mm 4.100.11 4.220.08 4.080.18 4.280.16 4.230.26 4.760.11†||
LVESD, mm 2.740.10 2.950.09* 2.830.23 2.830.12 2.370.23 3.30.08†
LVEF, % 68.602.04 62.782.44 64.54.8 68.64.25 80.62.61§ 64.51.4†
LV % FS 33.311.44 30.001.61 30.93.7 34.032.5 44.42.72§ 30.00.91†
Vcf, % 6.410.49 6.080.34 6.40.85 7.10.65 10.20.6§ 6.50.64†
MV E, mm/s 0.710.08 0.810.08 0.890.1 0.920.1 1.080.08 0.960.04
MV A, mm/s 0.440.04 0.500.04 0.610.1 0.640.1 0.580.04 0.430.08
MV E/A 1.60.11 1.60.08 1.40.35 1.50.1 1.90.26 2.30.02†
PWT, mm 0.480.01 0.490.02 0.530.04 0.540.03 0.560.02 0.630.04†
IVS, mm 0.510.0 0.510.02 0.540.04 0.570.03 0.560.01 0.630.001‡
LVmass, mg 66.43.63 70.852.31 68.53.2 82.89.0 82.68.73§ 116.14.80#†‡
Data are meanSE. A indicates atrial peak flow velocity; E, early peak flow velocity; FS, fractional shortening; HR, heart rate; IVS, interventricular septum thickness; LVEDD, left ventricular
end diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic dimension; MV, mitral valve; PWT, posterior wall thickness; SSPN, sarcospan; SSPN/,
SSPN-null; Vcf, velocity of circumferential shortening; WT, wild-type.
One-way ANOVA with Bonferroni correction was used to calculate significance, *P<0.05 (comparison between baseline wild-type and SSPN-deficient mice), †P<0.05 (comparison between
isoproterenol treated wild-type and SSPN-null mice), ‡P<0.05 (comparison between saline treated and isoproterenol treated SSPN-null mice), §P<0.05 (comparison between saline treated
and isoproterenol treated WT mice). ||P<0.05 (comparison between saline treated wild-type and isoproterenol-treated SSPN-null mice). #P<0.05 (comparison between saline treated SSPN-
null and isoproterenol-treated wild-type mice). Values reported as averages and errors presented as SEM.
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SSPN-Null Mice Are Responsive to b-Adrenergic
Stimulation
To determine whether the reduction of b-adrenergic respon-
siveness to isoproterenol in SSPN-null mice was caused by b-
adrenergic receptor down regulation, quantitative reverse
transcription–polymerase chain reaction analysis was
performed in 12-month-old untreated and isoproterenol-
treated (wild-type and SSPN-null) mice. Unlike wild-type mice,
SSPN-null mice did not exhibit enhanced cardiac contractility
(LVEF and LV fractional shortening, Figure 2E and 2F). We
found similar levels of b1, b2, b3 adrenergic receptor
expression in isoproterenol-treated SSPN-null hearts com-
pared with wild-type (Figure 4A through 4C). In summary,
A B
C D
E F
Figure 2. Cardiac dysfunction in SSPN-null mice in response to isoproterenol treatment. Echocardio-
graphic measurements change in mice as they age, (A) LV mass for 12- and 18-month-old WT and SSPN/
 mice. All mice used in (B through F) were 12 months of age. B, Echocardiographic measurements of LV
mass, mg were obtained after saline- and isoproterenol-administration to WT and SSPN-null (SSPN/)
mice. C, Increased left ventricle dimension in millimeters (mm) in SSPN-null (SSPN/) compared to WT
mice during diastole (LVEDD) and (D) systole (LVESD) measured by echocardiography after isoproterenol
challenge. E, Echocardiographic measurements of LV EF% and (F) LV FS% are shown for WT and SSPN-null
(SSPN/) mice after saline- and isoproterenol treatment. For (A), 12-month-old WT and SSPN-null
(SSPN/) mice (each, n=11) and 18-month-old WT and SSPN-null (SSPN/) mice (each, n=5) were
compared. For (B through F) samples are compared for saline (Sal, n=4) and isoproterenol (Iso, n=6)
treatment for each genotype. The data demonstrate the range of values, the black line symbol indicates
the mean of each data set. *P-values <0.05 were considered significant, and statistics were calculated
using 1-way ANOVA with Bonferroni post hoc test unless otherwise noted. For (A) *P<0.001 SSPN/
(18) vs WT (12), **P<0.001 SSPN/ (18) vs SSPN/ (12), #P=0.016 SSPN/ (18) vs WT (18),
P=0.340 WT (18) vs WT (12); (B) *P=0.006 SSPN/ (Sal) vs SSPN/ (Iso), the Kruskal–Wallis test was
utilized for **P=0.009 WT (Sal) vs SSPN/ (Iso), P=0.086 SSPN/ (Iso) vs WT (Iso); (C) *P<0.001
SSPN/ (Iso) vs WT (Iso), **P=0.006 SSPN/ (Iso) vs WT (Sal), P=0.076 SSPN/ (Sal) vs SSPN/
(Iso); (D) *P=0.006 SSPN/ (Iso) vs WT (Iso); (E) *P=0.002 SSPN/ (Iso) vs WT (Iso), **P=0.010 WT
(Iso) vs WT (Sal), P=0.077 WT (Iso) vs SSPN/ (Sal) and (F) *P=0.001 SSPN/ (Iso) vs WT (Iso),
**P=0.008 WT (Iso) vs WT (Sal), P=0.057 SSPN/ (Sal) vs WT (Iso). LV indicates left ventricular; LVEDD,
left ventricular end diastolic dimension; LV EF, left ventricular ejection fraction; LVESD, left ventricular
end systolic dimension; LV FS, left ventricular fractional shortening; SSPN, sarcospan; WT, wild-type.
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SSPN-null hearts appear to respond normally to isoproterenol
treatment in their upregulation of b-adrenergic receptor
mRNAs.
SSPN Deficiency Reduces Sarcolemmal Content
of Cardiomyopathy-Associated Proteins
SSPN associates with dystrophin, the dystroglycans, and the
sarcoglycans to form the DGC, which serves as a laminin-
binding receptor.36 In skeletal muscle, loss of SSPN reduced
expression of known disease genes, including dystrophin and
certain sarcoglycans, that encode proteins involved in muscle
cell adhesion, to the extracellular matrix.39 To determine
whether SSPN ablation in cardiac muscle similarly affects
these proteins, we examined DGC protein expression using
indirect immunofluorescence of cardiac cryosections obtained
from 4-month-old wild-type and SSPN-null mice. We found
that loss of SSPN reduced levels of dystrophin and sarcogly-
A B C
E
D
Figure 3. Isoproterenol treatment alters cardiac architecture of SSPN-null mice. A, Transverse cardiac sections from 12-month-old WT and
SSPN-null (SSPN/) mice were stained with H&E, revealing myocyte disarray, hypertrophy, and fibrosis in SSPN-nulls. White asterisks indicate
focal fibrotic regions, Bar, 50 lm. B, Masson’s trichrome staining identifies regions of collagen deposition (dark blue) in cardiac cross-sections
(axial, short axis). White asterisks indicate focal fibrotic regions. Bar, 900 lm. C, Fibrosis was quantified by measuring the area of collagen
staining in H&E-stained whole heart cross-sections after saline (Sal) and isoproterenol (Iso) administration. Data are represented as percentage
of fibrosis per total area. D, Enlarged H&E cardiac images reveal myofiber hypertrophy in SSPN-nulls after isoproterenol treatment. Bar, 50 lm.
E, Cardiac myofiber cross-sectional area was quantified after saline and isoproterenol challenge. H&E stained panels highlight fiber size
differences in WT and SSPN/ mice. For (C and E), data are presented as an average from 12-month-old, WT mice and SSPN-null (SSPN/)
that were saline- (Sal) (n=3) and isoproterenol-treated (Iso) (n=3). Statistical analysis was performed using 1-way ANOVA with Bonferroni post
hoc test and *P-values <0.05 were considered significant. For (C) *P<0.001 SSPN/ (Iso) vs WT (Sal), **P<0.001 SSPN/ (Iso) vs SSPN/
(Sal), #P=0.002 SSPN/ (Iso) vs WT (Iso), P=0.093 WT (Iso) vs WT (Sal) and (E) *P<0.001 SSPN/ (Iso) vs WT (Sal), **P<0.001 SSPN/ (Iso)
vs SSPN/ (Sal), #P=0.034 SSPN/ (Iso) vs WT (Iso), §P=0.013 WT (Iso) vs SSPN/ (Sal), P=0.091 WT (Iso) vs WT (Sal). H&E indicates
hematoxylin and eosin; SSPN, sarcospan; WT, wild-type.
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can subunits (a-, b-, d-, c- and SG) (Figure 5A), and thereby
affects localization of sarcolemmal adhesion complexes,
which may contribute to muscle pathology (Figure 5A). Even
though dystrophin levels were slightly increased in both wild-
type and SSPN-null hearts upon isoproterenol treatment,
SSPN-null hearts still exhibited reduced dystrophin relative to
wild-type (data not shown).
To determine whether SSPN loss affects expression of
adhesion complexes, we performed immunoblots examining
total protein levels (Figure 5B). The overall levels of utrophin,
dystrophin, a-/b-DG, and b-SG were slightly reduced in SSPN-
null muscle compared to wild-type (Figure 5B). b1D integrin
expression was increased in the SSPN-null hearts (Figure 5B),
similar to that reported in skeletal muscle.42 Overall, total
sarcoglycan expression levels were unchanged in SSPN-null
hearts compared to wild-type.
To quantitate expression of laminin-binding adhesion
complexes in SSPN-null hearts, we performed a DG pulldown
assay. Agarose-bound sWGA lectin chromatography selec-
tively binds to N-glycans bound to DG and associated
proteins. Using this approach, we can isolate adhesion
complexes associated with the DGC.2 Analysis of sWGA void
and eluate samples allow detection of unbound and DG bound
samples, respectively (Figure 5C and 5D). We found that
utrophin and dystrophin binding to DG was reduced in the
absence of SSPN. Loss of SSPN also negatively affected
binding of sarcoglycans (a-, b-, d- and c-SG) to DG
(Figure 5D). In the absence of SSPN, sarcoglycans bound
less tightly to DG (especially d- and c-SGs). Examination of
sWGA voids by immunoblot showed increased levels of
sarcoglycans in SSPN-nulls, indicating that they require SSPN
to effectively associate with the cardiac DGC. Although b1D
integrin was increased in the SSPN-null total protein blots
(Figure 5A), its binding to DG was greatly reduced in the
absence of SSPN (Figure 5D and 5E). We found that all
components of the DGC, along with utrophin and b1D
integrin, were present in sWGA eluates isolated from wild-type
hearts (Figure 5D). These data reveal that SSPN mediates
attachment of b1D integrin to DG and that loss of SSPN does
not alter membrane localization of b1D integrin. However, in
SSPN-null skeletal muscle, b1D integrin levels maintained
association with DG,42 revealing discernable differences in
cardiac and skeletal muscles in terms of association.
In SSPN-nulls, DG pulldown revealed significant changes
for dystrophin and b-DG only. Many of these DCG proteins,
however, were visibly reduced in SSPN-null hearts (n=5)
(Figure 5E). A schematic diagram (Figure 6) represents the
major consequences of SSPN ablation in cardiac tissue: (1)
destabilization of and almost complete loss of d- and c-SG
from the sarcolemma; (2) a-DG associates less tightly with
laminin in the extracellular matrix, reducing cell-to-cell
adhesion; (3) dystrophin levels are reduced; (4) functional
responsiveness to isoproterenol is reduced (cardiac output
unchanged) and ventricular dimensions increased; and (5) the
hypertrophic response is heightened upon isoproterenol
administration and aging.
A B C
Figure 4. SSPN-null mice have a blunted response to b-adrenergic stimulation. Relative changes in gene expression changes of b-adrenergic
receptors (b1, b2, and b3) upon isoproterenol challenge were assessed by qRT-PCR in cardiac muscle obtained from untreated (Untr) and
isoproterenol-treated (Iso) 12-month-old WT and SSPN-null (SSPN/) mice. A, Relative gene expression values of the ADRB1 gene encoding (b-
AR 1). (B) Relative gene expression values for the ADRB2 gene encoding (b-ΑR 2). (C) Relative gene expression values for the ADRB3 gene
encoding (b-AR 3) receptors in untreated (Untr) and isoproterenol-treated (Iso) WT and SSPN/ hearts. Data were normalized to mL32 (a
ribosomal protein) as an internal control and are presented as an average. All mice were 12 months of age. Data are presented as an average
from WT and SSPN-null (SSPN/) mice, either saline (Sal) (n=6) or isoproterenol-treated (Iso) (n=6) and error bars represent SEM. The Kruskal–
Wallis test was applied since data did not meet assumptions of normality and *P-values <0.05 were considered significant. For (A) *P=0.044
SSPN/ (Iso) vs WT (Sal), P=0.081 SSPN/ (Iso) vs SSPN/ (Sal), P=0.177 WT (Iso) vs WT (Sal); (B) *P=0.005 SSPN/ (Iso) vs SSPN/
(Sal), **P=0.020 SSPN/ (Iso) vs WT (Sal), P=0.091 WT (Iso) vs WT (Sal) and (C) *P=0.014 SSPN/ (Iso) vs SSPN/ (Sal), **P=0.018
SSPN/ (Iso) vs WT (Sal), #P=0.049 WT (Iso) vs SSPN/ (Sal), P=0.064 WT (Iso) vs WT (Sal). qRT-PCR indicates quantitative reverse
transcription–polymerase chain reaction; SSPN sarcospan; WT, wild-type.
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SSPN Attenuates Cardiac Damage in DMD Mice
In skeletal muscle, transgenic overexpression of SSPN
ameliorates DMD muscle disease by increasing abundance
of compensatory adhesion complexes (UGC and a7b1D
integrin) at the sarcolemma that restore connection of the
sarcolemma to the extracellular matrix.42 We investigated
whether overexpression of human SSPN in cardiac muscle of
dystrophin-deficient mdx mice (mdxTG) would alleviate fea-
tures of dystrophic cardiac disease. The mdx mice have a
A B
E
C D
Figure 5. Loss of SSPN influences expression of cardiomyopathy genes. (A) Transverse cardiac cryosections from WT and SSPN-null mice
(SSPN/) stained with antibodies against dystrophin (Dys), utrophin (Utr), dystroglycans (a- and b-DG), b1D-integrin (Itgb) and sarcoglycans
(a-, b-, d- and c-SGs), and SSPN. Bar, 50 lm. B, Total protein lysates obtained from WT and SSPN-null (SSPN/) mice were immunoblotted for
DGC and associated proteins. Equal protein samples (60 lg) were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. DG
pulldown assay, whole heart lysates were enriched by sWGA lectin chromatography, which binds DG and allows biochemical determination of
associations between members of DGC-associated complexes with DG, core components, in the presence or absence of SSPN. In (C)
immunoblots of DG void samples are shown and in (D) immunoblots of eluates containing DG associated proteins are shown. CB staining is
shown as a loading control. Densitometry was used to quantify immunoblots shown in (D) to determine relative changes in DGC and associated
proteins in SSPN-null (SSPN/) mice compared to WT and reported as normalized arbitrary units. All mice were 4 months old and similar
results were obtained for 12-month-old mice (data not shown). Immunoblot data are presented as an average (n=5) for WT and SSPN-null
(SSPN/), except for d-SG (n=3) for WT and SSPN-null (SSPN/), and error bars represent SEM. *P-values <0.05 were considered significant,
and statistics were calculated using 1-way ANOVA. For comparisons of protein expression levels in WT vs SSPN/ mice in (E) *P=0.003 Dys,
*P=0.04 b-DG, *P=0.009 SSPN, P=0.09 Utr, P=0.08 a-DG, P=0.120 Itgb, P=0.227 a-SG, P=0.065 b-SG, P=0.326 d-SG, P=0.208 c-SG. CB
indicates Coomassie blue; DGC, dystrophin-glycoprotein complex; Itgb, b1D-integrin; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel
electrophoresis; SSPN, sarcospan; sWGA, succinylated wheat germ agglutinin; WT, wild-type.
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mutation in the dystrophin gene and serve as a mouse model
of DMD with associated cardiomyopathy. Since mice utilized
in this study overexpress human SSPN under control of the a-
actin promoter, we compared relative protein expression
levels of the transgene in skeletal muscle and cardiac muscle,
shown in Figure S2. Improvements in skeletal muscle
pathology appear to positively impact cardiac function,49
however, not in aged mdx mice.50 Therefore, it is unclear
whether some of the ameliorative effects in mdxTG hearts
compared to mdx could be due to effects of SSPN overex-
pression in skeletal muscle. Using a well-documented assay,
we injected 13- to 15-month-old mice with EBD, an in vivo
tracer dye, to assess muscle fiber damage. Mdx mice
displayed substantial EBD uptake (13.32%) in cardiac tissue,
particularly in the septum and right ventricle (Figure 7A
through 7C). However, SSPN dramatically reduced membrane
damage in mdx cardiac muscle, as revealed by a reduction in
EBD incorporation in mdx cardiac myofibers (1.25%). In fact,
EBD staining of mdxTG cardiac muscle was restored to wild-
type levels (Figure 7A through 7C). We observed low, but
detectable, levels of EBD infiltration (1.02%) in SSPN-null
hearts (Figure 7A through 7C).
We analyzed several histological parameters of mdx
disease using the following assays: H&E histochemistry, oil
red staining (adipose deposition), and Masson’s trichrome
(collagen deposition). As expected, mdx hearts exhibited
extensive fibrosis as well as fat and collagen deposition
(Figure 7D). Overexpression of SSPN improved cardiac dis-
ease parameters in mdx hearts; however, localized regions of
damage still occurred in some areas of the SSPN-transgenic
mdx hearts. We expect that tissue histology can be improved
to an even greater extent with higher SSPN expression levels.
Figure 6. Schematic summarizing effects of SSPN loss in cardiac muscle. A schematic diagram illustrates
the changes that occur at the sarcolemma due to alterations in SSPN levels in WT and SSPN-null (SSPN/)
mice. Protein levels of the entire DGC as well as b1D-integrin (light purple) are depicted by changes in color
intensity. The sarcoglycans (a-, b-, c-, d-SGs; light orange) are depicted as transmembrane oval shapes.
Dystrophin (Dys; white) is shown on the cytoplasmic face of the sarcolemma membrane. Dystroglycan (a-,
b- DGs; light blue) levels do not change with SSPN levels. Changes to cardiac muscle fiber cross-sectional
area are shown by increased size. Alterations in left ventricular dimension are demonstrated for SSPN/
hearts, shown as increased LVEDD and LVESD. Glycosylation is depicted as black branches on both the
SGs and DGs. The extracellular matrix containing laminin to which DG associates is depicted as black lines.
This schematic summarizes the major consequences of SSPN loss including: (1) reduction in dystrophin
levels, (2) almost complete loss of d- and c-SG from the sarcolemma, (3) reduction in laminin binding in the
extracellular matrix reducing cell-to-cell adhesion, (4) blunted functional responsiveness to isoproterenol,
and (5) increased hypertrophic response to isoproterenol administration and aging. DGC indicates
dystrophin–glycoprotein complex; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular
end systolic dimension; SSPN, sarcospan; WT, wild-type.
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Improvement of disease at the tissue level was further
evidenced by the reduction of ANP (atrial natriuretic peptide)
expression in mdxTG hearts compared to mdx controls
(Figure 7E). Additional evidence of functional rescue was
the significant reduction of CK-MB (cardiac creatine kinase
isoform) in mdxTG mice compared to mdx mice (Figure 7F).
Human SSPN overexpression was able to increase levels of
key DGC- and UGC-associated proteins utrophin and b1D
A B C
E
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F
H
Figure 7. SSPN attenuates membrane damage in DMD hearts. A, Mice were injected with EBD to detect regions of membrane instability
(visualized by red fluorescence). Transverse cryosections of heart muscle from 12-month-old WT, SSPN-null (SSPN/), DMD model (mdx), and
mdx:SSPN-Tg (mdxTG) mice were stained with laminin antibodies (green) to visualize individual myofibers. Bar, 900 lm. B, Magnified (940)
images of representative sections from (A). Bar, 50 lm. C, Quantification of EBD-positive fibers (n=3 hearts per genotype). D, Cardiac muscle
from 4-month-old WT, mdx and mdxTG mice were stained with H&E, MT, and Oil Red (n=2). Bar, 50 lm. E, Relative changes in gene expression
changes of ANP were assessed by qRT-PCR in 4-month-old WT, mdx, and mdxTG hearts and number of mice utilized was (WT (n=4), mdx (n=5),
mdxTG (n=5). F, Serum CK-MB levels were detected in WT; mdx and mdxTG groups of mice (WT (n=5), mdx (n=6), mdxTG (n=5). G, Immunoblots of
sWGA cardiac eluates show changes in key proteins in WT, mdx and mdxTG hearts (n=3 experiments, samples from 3 different mice of each
genotype) whereas, in (H) Immunoblots show changes in laminin binding in a laminin overlay experiment (Laminin O/L) upon overexpression of
SSPN in WT, mdx and mdxTG hearts (n=3 experiments, samples from 3 different mice of each genotype). Equal sWGA protein samples (30 lg)
were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. CB staining is shown as a loading control. All data are presented
as averages and error bars are expressed as SEM. Statistics were performed by 1-way ANOVA with Bonferroni correction for individual groups in
(C through F) and *P-values ≤0.05 are indicated. For (C) *P=0.018 mdx vs WT, **P=0.027 mdx vs mdxTG, #P<0.001 SSPN/ vs WT; (E)
*P=0.003 WT vs mdx, **P=0.036 mdx vs mdxTG and (F) *P<0.001 mdx vs WT and **P=0.009 mdx vs mdxTG. ANP indicates atrial natriuretic
peptide; CB, Coomassie blue; CK-MB, cardiac creatine kinase; DMD, Duchenne muscular dystrophy; EBD, Evans blue dye; H&E, hematoxylin &
eosin; mdx, Duchenne muscular dystrophy mouse model; mdxTG, mdx mice overexpressing human sarcospan; MT, Masson’s trichrome; qRT-PCR
indicates quantitative reverse transcription–polymerase chain reaction; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis;
SSPN, sarcospan; sWGA, succinylated wheat germ agglutin; WT, wild-type.
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integrin, but not dystrophin (Figure 7G). Furthermore, the
presence of SSPN in mdxTG hearts increased laminin binding
in laminin overlay experiments compared to mdx controls
(Figure 7H). This indicates that SSPN increased cardiac cell
adhesion and was responsible for stabilizing the cardiac cell
membrane, leading to decreased EBD uptake in mdxTG hearts
and CK-MB in their bloodstream. Immunoblots showed that
the increase in laminin binding appeared dependent on SSPN
expression and not upon increasing levels of a-DG. The levels
of mouse and human SSPN are also shown; mouse SSPN is
also seen in mdx hearts, however, at a decreased level and
not discerned at this exposure. The increase in mouse SSPN
in the mdxTG could be due to enhanced SSPN expression;
however, likely some cross-reactivity exists between the
mouse SSPN antibody and the human SSPN protein
(Figure 7H).
SSPN Improves Cardiac Function in DMD Mice
To assess baseline cardiac parameters and function of mice
used in our study, we performed echocardiography on 10-
to 11 month-old wild-type, mdx and mdxTG mice. In the mdx
mice overexpressing SSPN (mdxTG), the heart weight/body
weight (HWt/BWt; mg/g) ratio was significantly increased to
6.170.15 in mdx mice compared to wild-type, whereas in
mdxTG mice the HWt/BWt ratio was 5.420.25 closer to the
wild-type value 5.330.11 (Figure 8A). In regard to function,
echocardiographic measurements of cardiac contractility
LVEF (%) were significantly higher in mdxTG mice
71.724.89 compared to mdx 59.124.96 and similar to
wild-type values 69.81.52 (Figure 8B). Similarly, LVFS% was
significantly improved in mdxTG mice (36.443.42) compared
to mdx values (27.381.27) and slightly higher than wild-type
values (34.061.07) (Figure 8C). Echocardiographic mea-
surements of cardiac dimension revealed a trend (although
not significant) that mdx (LVmass; mg) values were increased
to 81.48.79 compared to wild-type values of 64.512.24,
whereas hypertrophic growth was reduced in the mdxTG
hearts with values of 65.827.01 (Figure 8D). Ventricular
dimensions during diastole (left ventricular end diastolic
dimension; mm) were slightly smaller in mdxTG hearts with
values of 3.720.29 mm compared to dimensions of 4.14
0.17 mm in mdx and 4.020.08 mm in wild-type hearts,
while in systole (left ventricular end systolic dimension; mm)
lumenal dimensions were significantly decreased in mdxTG
hearts to 2.470.20 mm compared to 3.000.09 mm in
mdx and 2.650.07 mm in wild-type mice (Figure 8E). See
Table 2 for additional echocardiography parameters including
the values reported here. In Figure 8F, M-mode echocardio-
graphy images are shown for wild-type, mdx, and mdxTG mice
and demonstrate changes in lumenal width and contractility;
wild-type and mdxTG hearts had narrower ventricular lumenal
dimensions and heightened wall movement relative to mdx
hearts.
Our overall findings are summarized in a schematic that
illustrates the influence of SSPN on the integrity of the cardiac
sarcolemma and the expression of the DGC and a7b1
integrin. These findings reveal the important role that SSPN
plays in their localization at the cell surface. Furthermore,
functional consequences of SSPN loss can be attributed to a
reduction in important sarcolemmal proteins including SGs
and b1D integrin, which have important signaling and
structural roles and are known to be involved in cardiomy-
opathy and vascular dysfunction (Figure 9). Overexpression of
SSPN has been shown to improve the localization of utrophin
and improve membrane stability by increasing laminin binding
(Figure 9). This schematic summarizes our major findings
when SSPN is overexpressed including the following: (1)
Increased association of utrophin and b1D integrin with a-DG
in the DGC. (2) a-DG associates more tightly with laminin in
the extracellular matrix, increasing cell-to-cell adhesion. (3)
Increased membrane stability seen by the reduction in EBD
uptake and decreased detection of CK-MB in the blood sera.
(4) Tissue histology and cardiac function is improved in DMD
mice. (5) Cardiac hypertrophic growth is reduced in DMD
mice.
Discussion
To investigate the role of SSPN in the heart and hypertrophic
remodeling processes, we initiated studies exposing SSPN-
null mice to chronic b-adrenergic stimulation and uncovered a
physiological role of SSPN in regulating the cardiac hyper-
trophic response. In this study, 12-month-old SSPN-null mice
demonstrated increased heart weight/body weight after
isoproterenol administration, although SSPN-null mice had
increased body weights compared to wild-type after isopro-
terenol treatment. Even upon visual inspection, the isopro-
terenol-treated hearts were larger than their untreated
counterparts; at the tissue level, cross-sectional area of fibers
in SSPN-null hearts were noticeably larger than controls.
Consistent with these findings, echocardiographic measure-
ments indicated increased left ventricle wall thickness and
increased lumenal dimension in SSPN-null mice. This suggests
that b-adrenergic stimulation may have revealed the pheno-
typic consequence of SSPN-ablation before the onset of age-
related symptoms.
It was determined that the lack of physiological respon-
siveness to isoproterenol in the SSPN-null mice compared to
saline-treated controls was not due to b-receptor downreg-
ulation. These findings suggest that the blunted functional
response in SSPN-null mice may be due to alterations in
integrin signaling, which is involved in the hypertrophic
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response to b-adrenergic pathways. In this study, we found
specifically that integrin interactions with the DGC are
dependent on SSPN, although overall levels of b1D-integrin
are upregulated, likely due to sensing a reduction of
membrane stability when SSPN is absent. The contribution
of b1D-integrin to membrane stabilization and signaling that is
either unassociated or weakly associated with the DGC
remains unknown. Specifically, we demonstrate that b1-
integrin association with DG is dependent on SSPN. These
effects are expected to reduce integrin signaling, thus
diminishing the effects of b-adrenergic stimulation.51,52 This
in-depth analysis of SSPN-null cardiac muscle revealed
that loss of SSPN decreased abundance of the DGC at
the sarcolemma. We found that SSPN ablation disrupts
protein interactions that are crucial for association of b1D-
integrin and SGs with the DGC in the heart, as revealed by
sWGA precipitation. The effects on integrin binding to the
DGC likely underlie part of the mechanism for cardiac
dysfunction in SSPN-null mice, since it has an important
role in stabilizing the sarcolemma. Future studies will focus
A B C
D E F
Figure 8. Physiological evaluation of DMD mice overexpressing SSPN. To determine the effects of SSPN on mice exhibiting mdx cardiac
pathology we evaluated the following morphological and functional parameters. A, HWt/BWt; mg/g values obtained from 11- to 12 month-old
mice: WT (n=8), mdx (n=10), mdxTG (n=6). Echocardiographic data presented was obtained from mice 10 to 11 months of age: WT (n=12), mdx
(n=5), mdxTG (n=5) Echocardiographic assessment of contractility shows differences in (B) LV EF (%) and (C) LV FS (%) of WT, mdx and mdxTG
mice. D, LVmass (mg) measurements obtained by echocardiography indicate differences in ventricular mass in WT, mdx and mdxTG mice. E,
Echocardiographic measurements of LVEDD and LVESD in mm of WT, mdx and mdxTG mice. F, M-mode images obtained by echocardiography for
WT, mdx and mdxTG mice. Statistical analysis was performed using 1-way ANOVA with Bonferroni post hoc test and *P-values <0.05 are
indicated on the plots, all data presented as averages and error bars represent SEM. For (A) *P=0.003 mdx vs WT, **P=0.01 mdx vs mdxTG; (B)
*P=0.01 mdx vs WT, **P=0.01 mdx vs mdxTG; (C) *P=0.03 mdx vs WT, **P=0.01 mdx vs mdxTG; (D) P=0.061 mdx vs WT; and (E) ESD *P=0.03
mdx vs mdxTG, P=0.112 mdx vs WT. DMD indicates Duchenne muscular dystrophy; HWt/BWt, heart weight/body weight; LV EF, left ventricular
ejection fraction; LV FS, left ventricular fractional shortening; LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic
dimension; mdx, Duchenne muscular dystrophy mouse model; mdxTG, mdx mice overexpressing human sarcospan; SSPN, sarcospan; WT, wild-
type.
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on investigating effects of SSPN loss on abundance and
localization of a and b integrin subunits and the impact of
SSPN loss on Akt-dependent pathways that are altered in
skeletal muscle.42
To further test the phenotypic consequences of SSPN loss,
12-month-old mice were treated with isoproterenol to model
sustained adrenergic stimulation, eliciting compensatory
cardiac mechanisms that ultimately culminate in hypertrophy.
In response to isoproterenol treatment, the SSPN-null hearts
exhibited enhanced hypertrophy (increased HWt/BWt ratio
and LV mass) compared to wild-type. In this study, param-
eters of LV function indicated reduced contractility and
subsequently diastolic dysfunction, as evidenced by the
decreased fractional shortening and increased E/A ratio.
The EF (%) remained preserved in SSPN-null mice, and
subsequently cardiac output was unchanged in response to
b-adrenergic stimulation compared to controls. Interestingly,
B1KOmdx (dystrophin and b1-integrin) deficient mice also
demonstrate reduced LV function as well as blunted adren-
ergic responsiveness compared to controls.51 Additionally,
remodeling of the hypertrophied myocardium, together with
increased vulnerability of cardiomyocytes to hemodynamic
stressors, may cause changes in myocyte shape and distorted
alignment with the anisotropic laminar muscle, leading to a
reduction of ejection fraction and blunted b-adrenergic
response.53,54 Structural changes such as these in SSPN-null
cardiac tissue may underlie the ventricular remodeling and
reduced function that are evident in SSPN-null mice. Chamber
dimension is increased during both contractile phases,
indicating a decline in cardiac function. SSPN-null mice, after
b-adrenergic stimulation, phenocopy functional outcomes in
b1KO mice that display replacement fibrosis, LV chamber
dilation, increased septal and free wall thicknesses, and
depressed ventricular function (fractional shortening and
velocity of circumferential fiber shortening) compared to
controls.55
Isoproterenol treatment caused a substantial fibrotic
response in SSPN-null hearts and could be contributed by a
number of potential sources. It is feasible that decreased
membrane stability could increase cardiomyocyte suscepti-
bility to transient ischemia and myocardial damage, resulting
in localized fibrotic regions. Isoproterenol induces vasos-
pasms in susceptible individuals, which may contribute to an
infarct pattern of fibrosis.56 In the absence of vascular data,
we speculate that the large focal fibrotic areas in SSPN-null
hearts may result from increased susceptibility of SSPN-null
mice to vasoconstriction, or alternatively that increased cell
membrane fragility makes SSPN-deficient hearts more sus-
ceptible to transient ischemia. A previous study performed in
rat hearts described local reductions in dystrophin in areas of
myocardial injury post–isoproterenol treatment. The reduction
in dystrophin is thought to increase susceptibility to ischemic
injury.57 Similarly, the reduction of dystophin in the SSPN-null
hearts relative to wild-type controls increases susceptibility of
SSPN-nulls to isoproterenol-induced ischemic injury. Fibrosis
could also be attributed to integrin loss from the costameres,
since integrins colocalize to cardiomyocyte termini during
pathological stress.58 During development of hypertrophic
cardiomyopathy, b1-integrins are shed into the extracellular
matrix surrounding the cardiomyocytes, which induces a
integrin expression, particularly in the left ventricle.59 Tar-
geted deletion of the b1-integrin gene compromises myocyte
cell membrane integrity and leads to development of postna-
tal cardiac fibrosis.55 Furthermore, fibrosis can underlie
diastolic and systolic dysfunction, and heighten susceptibility
to cardiac arrhythmias.60,61 Disruption of the SG-SSPN
subcomplex in smooth muscle is known to cause vasospasm
in relevant murine models, leading to fibrosis and severe
cardiomyopathy.21,62 SSPN loss reduces SGs abundance at
the sarcolemma, with a greater reduction in d-SG and c-SG,
suggesting that they form a tighter association with SSPN
than other members of the complex. Future studies will be
Table 2. Summary of Echocardiographc Data Obtained From
DMD Mice
Baseline
WT (n=12) mdx (n=5) mdxTG (n=5)
Echo parameter
HR, bpm 527.519.2 536.220.0 547.417.7
LVEDD, mm 4.020.08 4.140.17 3.720.29
LVESD, mm 2.650.07 3.000.09 2.470.20†
LVEF, % 69.81.52 59.124.96* 71.724.89†
LV % FS 34.061.07 27.381.27* 36.443.42†
Vcf, % 6.750.32 5.880.35 8.030.74†
MV E, mm/s 0.690.04 0.840.11 0.60.04
MV A, mm/s 0.420.03 0.510.06 0.300.24†
MV E/A 1.660.07 1.660.06 2.10.11†‡
PWT, mm 0.490.01 0.560.02 0.550.04
IVS, mm 0.510.01 0.580.03* 0.570.03
LVmass, mg 64.512.24 81.48.79 65.827.01
Data are meanSEM. A indicates atrial peak flow velocity; DMD, Duchenne muscular
dystrophy; E, early peak flow velocity; FS, fractional shortening; HR, heart rate; IVS,
interventricular septum thickness; LVEDD, left ventricular end diastolic dimension; LVEF,
left ventricular ejection fraction; LVESD, left ventricular end systolic dimension; mdx,
Duchenne muscular dystrophy mouse model; mdxTG, mdx mice overexpressing human
sarcospan; MV, mitral valve; PWT, posterior wall thickness; Vcf, velocity of
circumferential shortening; WT, wild-type.
One-way ANOVA with Bonferroni post hoc test was utilized to determine differences
between groups, *P<0.05 (comparison between baseline WT and mdx mice), †P<0.05
(comparison between mdx and mdxTG mice), ‡P<0.05 (comparison between WT and
mdxTG mice). Values reported as averages and errors presented as SEM. Results for the
overall test were: HR (F=0.806), LVEDD (F=0.514), LVESD (F=0.036), LVEF (F=0.009),
LVFS (F=0.010), VCF (F=0.024), E (F=0.117), A (F=0.014), E/A (F=0.005) PWT
(F=0.047), IVS (F=0.025), LVmass (F=0.061).
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focused on determining whether SSPN loss reduces SGs in
the vasculature, thereby contributing to vasospasm.
Overexpression of SSPN ameliorated mdx pathology in
dystrophic hearts at the tissue level. EBD uptake was
extensively evident in mdx mice; however, the SSPN trans-
gene appears to have substantially restored membrane
stability, and mdxTG mice demonstrated EBD uptake levels
similar to wild-type. Reducing sarcolemmal fragility has been
well recognized as therapeutically valuable. Studies by
Metzger and colleagues have demonstrated the beneficial
consequences of in vivo administration of a membrane
sealant poloxamer 188 to dystrophic mice.63 The sarcolem-
mal stabilization provided by the sealant vastly improved
ventricular geometry and blocked development of acute
cardiac failure in mice during dobutamine-mediated cardiac
stress testing.64 SSPN overexpression in mdx hearts
increases utrophin and b1D-integrin complexes and further
promotes utrophin localization around the cardiac sar-
colemma, leading to increased laminin binding that promotes
cell-to-cell adhesion and stabilizes dystrophic cell mem-
branes. SSPN transgenic expression in mdx cardiac tissue
reduced levels of collagen deposition and fatty infiltrates, and
decreased levels of ANP, a cardiac stress marker. These
ameliorative effects by SSPN in mdx cardiac tissue are
strongly supported by the significant reduction of serum CK-
MB levels in the mdxTG mice. Serum CK measurements
provide a dependable index for membrane stability defects.
Examination of skeletal muscle CK levels in DMD patients is
Figure 9. Influence of SSPN on adhesion complexes in cardiac muscle. A schematic diagram illustrates
the changes that occur at the sarcolemma due to overexpression of human SSPN in mdx and mdxTG mice.
Protein levels of the entire DGC as well as the a7/b1D-integrin complexes (light purple) are depicted by
changes in color intensity. SSPN (green) is represented as a 4-transmembrane-spanning protein, where
dark green represents its 3-fold overexpression. The sarcoglycans (a-, b-, c-, d- SGs; light orange) are
depicted as transmembrane oval shapes. Dystrophin (Dys; white) is shown on the cytoplasmic face of the
sarcolemma membrane. Dystroglycan (a-, b-DGs; light blue) levels do not change with SSPN levels.
Glycosylation is depicted as black branches on both the SGs and DGs. CK-MB is shown as a green sphere
and EBD is depicted as a red square. Black lines indicate laminin in the extracellular matrix to which a-DG
and the DGC associate.This schematic summarizes the major findings when SSPN is overexpressed
including: (1) increased association of utrophin and Itgb to the DGC, (2) increased laminin binding, (3)
improved membrane stability, (4) improved tissue histology and cardiac function in DMD mice, and (5)
reduced cardiac hypertrophy. CK-MB indicates cardiac creatine kinase; DGC, dystrophin–glycoprotein
complex; DMD, Duchenne muscular dystrophy; EBD, Evans blue dye; mdx, Duchenne muscular dystrophy
mouse model; Itgb, b1D-integrin; mdxTG, mdx mice overexpressing human sarcospan; SSPN, sarcospan;
SSPN, sarcospan.
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routinely performed to assess the level of muscle membrane
damage and is an early marker for DMD in undiagnosed
patients. Although our assay for cardiac-specific CK-MB
reliably detects this isoform, we cannot rule out a contribution
of CK-MB from skeletal muscle. Normally skeletal muscle
produces low levels of CK-MB (1%); however, regenerative
cycles in skeletal muscle commonly seen in muscular
dystrophy causes increased CK-MB expression.65 In our
study, the restoration of tissue pathology (H&E and Masson
Trichrome) and membrane stabilization (EBD uptake and
increased laminin binding) in mdxTG compared to mdx hearts
provide evidence of direct effects of SSPN overexpression in
the heart. Therefore, it is reasonable to expect that SSPN
overexpression in the heart can reduce leakage of CK-MB into
the bloodstream.
Functional improvement was also seen in the hearts of
mdxTG mice, which showed significantly enhanced contrac-
tile performance compared to mdx hearts, and in fact
restored them to WT values. Overall, the hearts of mdxTG
mice were less hypertrophic than mdx hearts and exhibited
improvements in ventricular geometry. Since mdx mice
begin to exhibit cardiac symptoms around 10 months,66 we
utilized 10- to 11-month-old mice for this study. Limita-
tions exist; however, since mdx mice do not display severe
cardiac disease, the functional improvement by SSPN
overexpression was modest, although significant. Increased
levels of sarcolemmal proteins including utrophin and b1D
integrin are expected to stabilize the cell membrane. This
coupled with enhanced cellular adhesion mediated by SSPN
may protect against cardiomyocyte loss, improve integrity
of cardiac muscle, and subsequently restore function.
Future studies will examine the ability of SSPN to rescue
severe dystrophic cardiac disease in mdx:utr-het mice that
have reduced expression of utrophin, a compensatory
homologue of dystrophin. From these studies it can be
determined that SSPN has potential to ameliorate pathology
and subsequently improve cardiac performance in DMD
mice.
Presently, disease-associated mutations have not been
identified in the SSPN gene.67 The role of SSPN in cardiac and
skeletal muscle is complex, and we anticipate that many
functions remain undiscovered. Several genome-wide associ-
ation studies suggest a role for SSPN in disease, since various
polymorphisms that occur in the SSPN gene locus 12p11.2
were found to positively correlate with increased waist
circumference and LV mass in several extended and large
families.68 It appears that the role of SSPN in the heart is
stabilization of sarcolemmal proteins that protect against
contraction-induced damage and participation in signaling,
which promotes cardiac function. Furthermore, the close
physical association of SSPN with the DGC and integrins
suggests its importance in mediating interaction between
these complexes, which, when mutated or absent, cause
cardiac disease, whereas overexpression of SSPN restores
cardiac function and tissue pathology in mdx mice, suggesting
that it may hold promise as a future therapeutic option.
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